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See Article, pages 922–927Paracentesis is reported for the treatment of ascites since the
time of Hippocrates (460–370 BC). The ﬁrst detailed description
of the procedure was made by Celsus (30 BC–50 AC). The tech-
nique consisted in opening the abdominal wall by a puncture
with a cautery or a scalpel and inserting a cannula with a proxi-
mal end curved outward or one that had a rounder protuberance
in the middle to avoid its loss into the peritoneal cavity [1]. Sanc-
torious Sanctorio (1561–1636), a surgeon from Padova Univer-
sity, designed the ﬁrst trocar for paracentesis (a round needle
enclosed within a cannula through which ascitic ﬂuid was able
to ﬂow upon withdrawal of the needle). This was a fundamental
advance since the trocar permitted the control of the amount of
ascites extracted, as well as easy repetition of the procedure. Jean
Palfyn (1644–1730), a Belgian gynecologist, was the ﬁrst to pro-
pose the left lower abdominal quadrant for trocar insertion [1].
There have been many attempts to prevent complications
associated with paracentesis. Paul of Egina (625–690), a byzan-
tine physician, suspected that some complications were related
to alterations in circulatory function. He recommended a close
monitoring of vital signs, interrupting the procedure upon detec-
tion of a weakening of the pulse [1]. Pierre Dionis (1643–1718),
professor of Surgery in Paris, ﬁrst pointed out the beneﬁcial
effects of abdominal compression after paracentesis to reduce
the re-accumulation of ascites. Alexander Monro, a Scottish sur-
geon founder of the Edinburgh Medical School, designed a girdle
speciﬁcally for patients with ascites treated by paracentesis [1].
The intra-peritoneal instillation of wine was also used for this
purpose up to the end of the 18th century. Intra-peritoneal
adrenaline was still recommended in the 1930s.
Paracentesis was abandoned in the 1950s–1960s concomi-
tantly with the introduction of the modern diuretics. The article
by Hecker and Sherlock in 1956 [2] showing that the rapid
removal of ascites by paracentesis was followed by a impairment
in circulatory function, renal failure and death, together with the
high prevalence of local complications related to the large size of
the trochars were also important features in the discointinuationJournal of Hepatology 20
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lence of local complications was also a major problem due to
the large size of the trocars. Two articles from the Barcelona Liver
Unit published in the 1980s, however, reposition paracentesis in
the therapeutic armamentarium of cirrhotic ascites. They demon-
strated that paracentesis, if performed with small trocars, under
strict sterile conditions and in association with plasma volume
expansion with albumin, was more effective than diuretics in
the management of ascites and associated with a lower incidence
of complications [3,4]. Paracentesis associated with intravenous
albumin is now considered the treatment of choice of tense asci-
tes [5].
Refractory ascites, as deﬁned by the ascites that cannot be
managed by medical therapy either due to a lack of response to
maximal diuretic treatment or because patients develop diure-
tic-induced complications, is a relatively frequent complication
in cirrhosis. It is present in approximately 10% of patients admit-
ted to hospital for tense ascites. Therapeutic paracentesis associ-
ated with intravenous albumin is the treatment of choice in these
patients because it is very effective, rapid and associated with
few complications. In most centers, patients with refractory asci-
tes are treated by scheduled paracentesis (repeated every 2–
3 weeks) in single day hospitalization regime (admission in the
morning and discharge in the afternoon).
During the past 50 years, several procedures aiming at
improving the treatment of refractory ascites have been devel-
oped. The ﬁrst was the Rhone-Poulenc Ascites Reinfusion Appara-
tus (Rhodiascit). It consisted in a device that removed ascites
through an intra-abdominal catheter, concentrating the ﬂuid by
pressure ﬁltration, and infusing the concentrate through an intra-
venous catheter [6]. The ﬁltered water was drained to a plastic
bag connected to the ﬁlter. A high incidence of local side effects,
cardiovascular complications and particularly symptomatic
severe intravascular coagulation, were major problems and the
procedure was abandoned.
The peritoneo-venous shunting (PVS) consisted in a multi-
perforated intra-peritoneal tube connected to a subcutaneously
implanted unidirectional pump that permitted the passage of
the ﬂuid from, but not to, the abdominal cavity and a second tube
that subcutaneously reached the superior vena cava through the
internal jugular vein [7]. When ascites was signiﬁcant, it13 vol. 58 j 850–852
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circulated through the prosthesis in favour of a pressure gradient
(positive in the peritoneum, negative in the intra-thoracic circu-
lation). On the contrary, the ﬂow decreased or even stopped if
central venous pressure increased, thus preventing ﬂuid over-
load. Many studies demonstrated that PVS was associated with
major improvement in circulatory and renal function and higher
response to diuretics in patients with refractory ascites. However,
soon it became clear that this effectiveness was counterbalanced
by a high incidence of complications, including obstruction of the
prosthesis either at the intravenous end or in the valve, coloniza-
tion of the prosthesis by bacteria, leading to intractable infections
and plastic peritonitis with intestinal obstruction. These compli-
cations could not be prevented by a new design of the valve (Den-
ver shunt) or by the insertion of a thrombo-resistant titanium tip
in the vascular end of the prosthesis [8]. After being used for
years in thousands of patients, PVS could not resist the ﬁrst ran-
domized controlled trial comparing the shunt with therapeutic
paracentesis associated with i.v. albumin, and was therefore
abandoned [9].
Transjugular intrahepatic porta-caval shunt (TIPS) is also
associated with improvement in systemic hemodynamics and
renal function. Many patients with refractory ascites regain a
normal renal ability to excrete sodium and can be maintained
free of ascites without sodium restriction and diuretics. Five ran-
domized controlled trials comparing paracentesis associated with
i.v. albumin versus TIPS, in patients with cirrhosis and ascites,
have been reported. Three of them were performed in patients
with refractory ascites [10–12]. In the remaining two, patients
with both refractory and recidivant ascites were included
[13,14]. Recidivant ascites deﬁnes a patient population without
refractory ascites that requires frequent admission to the hospital
(more than 3 per year) due to re-accumulation of ascites related
to different causes (poor sodium restriction, insufﬁcient diuretic
dosage, treatment with non-steroidal anti-inﬂammatory drugs).
Results obtained by TIPS were clearly worse in terms of improve-
ment of ascites and survival in the three trials performed in
patients with refractory ascites than in those including refractory
and recidivant ascites. Interestingly, ﬁve meta-analyses have also
been reported regarding these 5 randomized trials but none of
them took into account the differences in the type of patients
included [5]. Therefore, their results should be regarded cau-
tiously. In the three trials performed in patients with refractory
ascites, the long-term control of ascites was signiﬁcantly better
in patients treated by TIPS than in those treated by paracentesis.
The incidence of hepatic encephalopathy, however, was signiﬁ-
cantly higher in patients treated by TIPS. There was no difference
in survival. Based on these studies, total paracentesis associated
with i.v. albumin is considered the treatment of choice for refrac-
tory ascites in cirrhosis.
The current issue of the Journal of Hepatology reports a study
assessing a new device, the Automated Low Flow Pump System,
in 40 patients with refractory ascites [15]. It consists of an
intra-peritoneal catheter connected to a subcutaneously
implanted battery-powered device that moves ﬂuid from, but
not to, the peritoneal cavity and a second catheter that connects
subcutaneously the pump to the urinary bladder. Patients, there-
fore, directly urinates the ascites. The system has internal sensors
that monitor the pressure in the peritoneal cavity and bladder in
order to prevent pump operation when pressure in the abdomen
is low or that in the bladder is high. The volume and time of infu-
sion can also be programmed. The surgical procedure (1 h)Journal of Hepatology 201requires general anesthesia. The number of complications
reported within the ﬁrst 6 months, some related to the underly-
ing cirrhosis but other related to the device, was high. A signiﬁ-
cant proportion of patients had to be re-operated to correct
malfunction of or complications related to the prosthesis or to
remove the device. Some complications were similar to those
observed with the PVS. Forty percent of patients required para-
centesis. The follow-up period was insufﬁcient to assess the inci-
dence of long-term complications, particularly plastic peritonitis
related to the intra-abdominal catheter. Two major conclusions
can be drawn from this study. The ﬁrst is that the device, surgical
technique, and patient selection should be improved to reduce
the prevalence of complications. The second is that investigators
and manufacturers should take into account the history of para-
centesis, particularly those features indicating that any device for
refractory ascites must be compared with paracentesis associated
with i.v. albumin in a sufﬁciently powered randomized controlled
trial prior to advocate its widespread use.
A ﬁnal question is if a potential candidate for liver transplan-
tation could beneﬁt from the Automated Low Flow Pump System.
In fact, PVS was formally contraindicated in these patients
because it could induce plastic peritonitis, a complication also
described in patients treated with the new system [15]. Plastic
peritonitis makes liver transplantation difﬁcult to be performed,
or may even prevent it. Colonization of the prosthesis during bac-
terial infections or transient episodes of bacteremia may lead to
severe sepsis, acute-on-chronic liver failure and death. Local
complications may further worsen the already complex clinical
course of patients with advanced liver failure. Finally, the pros-
thesis has to be removed prior to liver transplantation in all cases,
because it will be no longer required and it is a source of potential
complications.Conﬂict of interest
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